



Transforming PCR Testing for Infectious Diseases @ANYWHERE™

LEADERSHIP TEAM

EXTENSIVE DIAGNOSTIC EXPERIENCE

Kevin Kraus, MBA
Chief Executive Officer

Mark Kelleher, PhD
EVP, Research & Development

Jay Foust, MBA
EVP, Business Development

Shelle Pourmanafzadehardabili
VP, Business Operations

BOARD OF DIRECTORS

Barbara Handelin, PhD
Board Member, pioneer in PCR

Russ Hullet
Co-Founder, Board Director

Bob Blomquist
Co-Inventor, Board Chair

KEY ADVISORS

Chuck Henry, PhD
Professor Engineering, CSU

Tony Shuber
Diagnostics Advisor & Sr. Executive

Mickey Urdea, PhD
Diagnostics Advisor & pioneer

INTELLECTUAL PROPERTY

- Landmark US Patent #12,344,889 issued July 2025
- Broad patent estate with 5 additional patents pending

ASK / USE OF FUNDS \$2.75M

- Complete STI data package
- Complete 510(k)-ready sample collection kit & @ANYWHERE device proof-of-concept
- Prosecute patents
- Generate customer/OEM sales

PROBLEM

- 14M people die annually from infectious diseases like tuberculosis, respiratory infections, and sexually transmitted infections (STIs).
- People lack access to rapid, accurate & affordable PCR testing.
- PCR is the gold-standard for infectious disease testing but it is complex, expensive, and still stuck in the lab.

OUR SOLUTIONS

- Direct-to-PCR platform technologies that deliver rapid, accurate, and affordable testing for infectious disease @ANYWHERE.

Sample Extraction Testing



Simplify conventional PCR



Moving PCR out of the lab with @ANYWHERE device

CLINICALLY VALIDATED

- >590,000 patients tested for SARS-CoV-2 using technologies developed by predecessor company, Summit Biolabs.
- 5-14x faster, 7x lower cost and and turnaround time with same high accuracy compared to conventional PCR.
- Non-toxic chemistries with ≥7-day sample stability at 40°C.
- Proof-of-concept: viruses (Flu+COVID), and bacteria (STI's chlamydia, gonorrhea) with further studies planned on challenging pathogens (e.g., tuberculosis).

TARGET MARKET OPPORTUNITY

- \$17B target market global molecular diagnostics market (labs and manufacturers), spanning reagents, sample collection, and lab and point-of-care PCR.
- Establish partnerships for platform technologies, including @ANYWHERE device, for sales & licensing opportunities.
- Drive DirectAmp™ reagent sales beginning with RUO, then IVD (ISO 13485) through partners & distributors.

IMPACT

- Change the future of PCR diagnostics for infectious disease to expand access, accelerate treatment, reduce the spread of disease, and ultimately save lives.